TUMOR SUPPRESSION BY PARP INHIBITORS IS POTENTIATED BY c-MET INHIBITION

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2016年 / 6卷 / 03期
关键词：
D O I：
10.1158/2159-8290.CD-RW2016-017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：229 / 229
页数：1
相关论文
共 50 条
  • [21] c-MET Inhibitors in the Treatment of Lung Cancer
    Gozdzik-Spychalska, Joanna
    Szyszka-Barth, Katarzyna
    Spychalski, Lukasz
    Ramlau, Katarzyna
    Wojtowicz, Jerzy
    Batura-Gabryel, Halina
    Ramlau, Rodryg
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (04) : 670 - 682
  • [22] Synthesis and SAR of diaminopyrimidines as c-Met inhibitors
    Weinberg, Linda R.
    Albom, Mark S.
    Angeles, Thelma S.
    Diebold, James L.
    Husten, Jean
    Lisko, Joseph G.
    Milkiewicz, Karen L.
    Murthy, Seetha
    Ott, Gregory R.
    Ruggeri, Bruce A.
    Theroff, Jay P.
    Underiner, Ted L.
    Dorsey, Bruce D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [23] Synthesis of benzoxazepine diaminopyrimidines as c-Met inhibitors
    Theroff, Jay P.
    Aimone, Lisa D.
    Albom, Mark S.
    Angeles, Thelma S.
    Brown, Rebecca
    Dorsey, Bruce D.
    Galinis, Deborah
    Grobelny, Jennifer V.
    Herbertz, Torsten
    Husten, Jean
    Kocsis, Laura S.
    LoSardo, Christine
    Miknyoczki, Sheila J.
    Murthy, Seetha
    Rolon-Steele, Damaris
    Underiner, Ted L.
    Worrell, Candace S.
    Zeigler, Kelli
    Zificsak, Craig A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [24] Safety and Tolerability of c-MET Inhibitors in Cancer
    Puccini, Alberto
    Marin-Ramos, Nagore I.
    Bergamo, Francesca
    Schirripa, Marta
    Lonardi, Sara
    Lenz, Heinz-Josef
    Loupakis, Fotios
    Battaglin, Francesca
    DRUG SAFETY, 2019, 42 (02) : 211 - 233
  • [25] Safety and Tolerability of c-MET Inhibitors in Cancer
    Alberto Puccini
    Nagore I. Marín-Ramos
    Francesca Bergamo
    Marta Schirripa
    Sara Lonardi
    Heinz-Josef Lenz
    Fotios Loupakis
    Francesca Battaglin
    Drug Safety, 2019, 42 : 211 - 233
  • [26] c-MET Inhibitors in the Treatment of Lung Cancer
    Joanna Goździk-Spychalska
    Katarzyna Szyszka-Barth
    Łukasz Spychalski
    Katarzyna Ramlau
    Jerzy Wójtowicz
    Halina Batura-Gabryel
    Rodryg Ramlau
    Current Treatment Options in Oncology, 2014, 15 : 670 - 682
  • [27] Synthesis of triazolotriazine derivatives as c-Met inhibitors
    Guo, Yuting
    Peng, Xia
    Ji, Yinchun
    Zhang, Yitong
    Ding, Jian
    Zhan, Zhengsheng
    Ai, Jing
    Duan, Wenhu
    MOLECULAR DIVERSITY, 2021, 25 (02) : 839 - 846
  • [28] The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials
    Varkaris, Andreas
    Corn, Paul G.
    Gaur, Sanchaika
    Dayyani, Farshid
    Logothetis, Christopher J.
    Gallick, Gary E.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (12) : 1677 - 1684
  • [29] Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition
    Tahereh Damghani
    Maryam Elyasi
    Somayeh Pirhadi
    Zahra Haghighijoo
    Somayeh Ghazi
    Molecular Diversity, 2022, 26 : 1411 - 1423
  • [30] The role of c-Met inhibition for neuroblastoma treatment
    Zage, Peter
    Scorsone, Kathy
    Zhang, Linna
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345